NEWS!!!
Cobalis Appoints Three Pharmaceutical Industry Executives to Board
Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, is pleased to announce today the appointment of S. Wayne Kay, Ellen McDonald, and Thomas H. Silberg to its board of directors. The appointees will replace three resigning directors, two of which remain as officers of the Company. With these appointments, Cobalis’ board will continue to be comprised of seven members, including the Company’s chairman, Radul “Rudy” Radovich, a founding shareholder, and CEO Dr. Gerald J. Yakatan, who will be the only management member of the Board.
"We are pleased to have attracted such an array of accomplished pharmaceutical industry professionals to the Board,” said Rudy Radovich. “We look forward to benefiting from their insight as the Company strives to execute on its goals. I would also like to thank those resigning members of the Board for their support in advancing the Company to this stage, and for recognizing the need for new Board members with the Company at this stage in its development.”
Mr. Kay, 56, is an experienced pharmaceutical executive with extensive senior level management experience in both entrepreneurial and larger companies. He has served as President and CEO of Quidel Corporation, Health Industry Distributors Association, and Enzymatics Inc. Previously, Mr. Kay was the senior vice president of Neoforma and was President of SmithKline Diagnostics, Inc. He now serves as an interim executive advisor to the management and boards of several early stage companies, including a life sciences tool company; an early stage company focused on development of a non-invasive cardiac output measurement technology; and a clinical chemistry reagent medical device company.
Ms. McDonald, 45, is Senior Vice President, Business Operations for Chugai Pharma USA, LLC, having previously served as a strategic commercialization consultant for small to mid-sized biotechnology, pharmaceutical and medical device companies. Previously, she served for three years as Senior Vice President, Cardiovascular Marketing and Medical with Bristol-Myers Squibb. For the prior twelve years, Ms. McDonald worked for Johnson & Johnson, Inc., progressing from sales representative to Vice President, Oncology Franchise, of the Company’s Ortho Biotech Inc. subsidiary.
Mr. Silberg, 60, serves as President of Abraxis Pharmaceutical Products (APP), a division of Abraxis BioScience that manufactures and markets a broad range of injectable drugs in the areas of oncology, critical care, and anti-infectives. Prior to joining Abraxis, Mr. Silberg served as Chief Operating Officer at Tercica, Inc. and Ligand Pharmaceuticals Inc. Mr. Silberg commenced his pharmaceutical career with Hoffmann-Laroche, Inc., where he spent 27 years, rising from salesman to Vice President, Business Operations.
Stepping down from the Board of Directors is Chas Radovich, a co-founder of the Company and a director since 2003. Mr. Radovich, the son of Rudy Radovich, is also a shareholder of the Company and will continue as President. In addition, Ernest T. Armstrong, a director of Cobalis since 2004 and the Company’s Chief Scientific Officer, and Larry May, a director of Cobalis since 2004, have both stepped down from the Board. Mr. Armstrong will continue to serve the company as Chief Scientific Officer, and Mr. May will continue to serve on the Company’s Scientific Advisory Board. The Board thanks Messrs. Radovich, Armstrong and May for their service, dedication and contributions to the company in their role as directors.
About Cobalis Corp.
AI
